Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric acute promyelocytic leukemia treatment study
2008-002311-40Phase 3Terminated
- Sponsor
- Italian Association of Pediatric Hematology and Oncology
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tretinoin, idarubicin, mitoxantrone, cytarabine, methotrexate and 3 more in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Italian Association of Pediatric Hematology and Oncology. Primary endpoints: Achievement of molecular complete remission, Duration of remission and relapse outcomes and 3 more. Started Mar 2009; status: terminated.
02
Drugs
tretinoinidarubicinmitoxantronecytarabinemethotrexate
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on 2008-002311-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002311-40.